Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: aspirin plus clopidogrel Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)

NCT00799396
View directory record Official record
Conditions
Platelet Aggregation Inhibitors, Coronary Heart Disease
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

NCT01586975
View directory record Official record
Conditions
Stroke, Myocardial Infarctions
Interventions
Clopidogrel, Aspirin 81 mg, Aspirin >300 mg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Oct 2, 2026, 9:15 AM EDT
Recruiting Phase 4 Interventional

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

NCT06228456
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 60mg, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

NCT01830543
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
2,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
86
States / cities
Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

NeuroCognition After Carotid Recanalization

NCT04219774
View directory record Official record
Conditions
Cognition Disorder, Stroke, Occlusion Carotid
Interventions
Endovascular intervention, Aspirin and Clopidogrel (maximal medical Therapy)
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 2, 2026, 9:15 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin plus clopidogrel, prasugrel or ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Not listed Phase 4 Interventional

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

NCT03150667
View directory record Official record
Conditions
Chronic Kidney Diseases, Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

NCT02217501
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Clopidogrel, Acetylsalicylic acid (ASA)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Denver, Colorado • Davenport, Iowa • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 2, 2026, 9:15 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

NCT01433978
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Avatrombopag, Standard of care
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 2, 2026, 9:15 AM EDT
Not listed Phase 4 Interventional

Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

NCT04502017
View directory record Official record
Conditions
Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion
Interventions
ASA plus Clopidogrel, Genetic-Tailored AntiThrombotic Strategy, Half-Dose of novel OAC
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 2, 2026, 9:15 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.

NCT01011257
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Asprin, Clopidogrel
Drug
Lead sponsor
Neil Kleiman, MD
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

PROMUS Element Plus US Post-Approval Study

NCT01589978
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00020189
View directory record Official record
Conditions
Head and Neck Cancer, Thromboembolism
Interventions
acetylsalicylic acid, alvocidib, clopidogrel bisulfate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 2, 2026, 9:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Performance Evaluation of T-TAS 01 PL Chip

NCT03621020
View directory record Official record
Conditions
Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
Interventions
T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
21 Years and older
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
5
States / cities
San Francisco, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

EVOLVE Short DAPT Study

NCT02605447
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
89
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 2, 2026, 9:15 AM EDT
Terminated Phase 3 Interventional

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

NCT00243178
View directory record Official record
Conditions
Atrial Fibrillation, Vascular Risk
Interventions
clopidogrel (SR25990C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
6,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 19, 2009 · Synced Oct 2, 2026, 9:15 AM EDT
Terminated Phase 3 Interventional Results available

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

NCT00991029
View directory record Official record
Conditions
Ischemic Attack, Transient
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
4,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
147
States / cities
Chandler, Arizona • Tucson, Arizona • Carmichael, California + 95 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

NCT02293395
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,037 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
49
States / cities
Alexander City, Alabama • Banning, California • Sylmar, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 2, 2026, 9:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease

NCT03174990
View directory record Official record
Conditions
Peripheral Arterial Disease, Clopidogrel, Poor Metabolism of
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 2, 2026, 9:15 AM EDT
Recruiting Not applicable Interventional

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

NCT07613840
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomics of Antiplatelet Response - I

NCT01815008
View directory record Official record
Conditions
Platelet Aggregation, Platelet Transcriptome, Coronary Artery Disease
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

NCT01557335
View directory record Official record
Conditions
Platelet Aggregation
Interventions
Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
Drug
Lead sponsor
POZEN
Industry
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Results available

Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease

NCT01107925
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
prasugrel, clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Jacksonville, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Oct 2, 2026, 9:15 AM EDT